Streetbeat News

Revenues

USIO

Usio reported Q4 sales of $19.363M, missing the analyst consensus estimate of $20.427M by 5.21%. This represents a 3.52% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:17 pm

RH

RH forecasts an 8-10% revenue growth for FY24 and anticipates Q1 revenues to experience a negative low-single digit growth. This outlook suggests a cautious but optimistic view for the full year, while acknowledging near-term challenges.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:11 pm

FUL

H.B. Fuller has reiterated its financial guidance for FY24, expecting adjusted EPS of $4.15-$4.45, in line with estimates of $4.31. The company anticipates net revenue growth of 2% to 6%, with organic revenue growth ranging from flat to 3% year-on-year. Adjusted EBITDA is projected to be between $610 million and $640 million, indicating a 5% to 10% growth year-on-year. Operating cash flow is forecasted to be in the range of $300 million to $350 million.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:09 pm

RUM

Rumble anticipates revenue growth starting Q2 2024 due to new revenue engines and reduced creator commitments, aiming for breakeven in 2025.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:08 pm

IVA

Inventiva reported a significant increase in its FY23 revenues to €17.5 million, up 43.4% from €12.2 million in 2022, driven by licensing agreements with CTTQ and Hepalys for the development of lanifibranor in MASH/NASH. However, the company's net loss widened to €110.4 million from €54.3 million due to increased R&D expenses, particularly for the NATiV3 Phase III clinical trial and the LEGEND Phase IIa trial. Cash and equivalents decreased to €26.9 million, with a material uncertainty regarding the company's ability to continue as a going concern. Inventiva received significant financing in 2023, including a €35.7 million capital increase and royalty certificates issuance, and upfront and milestone payments from CTTQ and Hepalys.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:04 pm

NVCR

NovoCure (NASDAQ:NVCR) has received mixed analyst ratings over the past three months, with a recent shift towards a more neutral stance. The average 12-month price target for NVCR has increased to $20.00, reflecting an 11.11% rise from the previous target of $18.00. Analysts from firms like HC Wainwright & Co. and JP Morgan have adjusted their price targets and ratings, indicating a nuanced view of NovoCure's market position. Despite challenges in net margin and debt management, NovoCure has shown notable revenue growth and a strong return on equity.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 8:01 pm

CTAS

DRCT

GMDA

LIXT

MRDB

PAYS

VLD

U.S. stocks showed mixed performance with the Dow Jones gaining, while the NASDAQ slightly fell. Cintas Corporation reported better-than-expected Q3 results and raised FY24 guidance. Lixte Biotechnology, MariaDB, and PaySign saw significant stock increases, whereas Gamida Cell, Direct Digital Holdings, and Velo3D experienced sharp declines. Gold and silver prices rose, while oil and copper saw decreases.

Portfolio Pulse from Avi Kapoor

March 27, 2024 | 7:24 pm

UBER

Analyst ratings for Uber Technologies (NYSE:UBER) show a predominantly bullish outlook, with 35 analysts offering perspectives ranging from bullish to bearish over the last three months. The average 12-month price target is $81.66, marking a 14.07% increase from the previous average of $71.59. Recent actions by analysts include raising ratings and price targets, reflecting positive sentiment towards Uber's market performance and financial health. Uber's market capitalization, revenue growth, net margin, ROE, and ROA all indicate strong market presence and financial performance, with a debt-to-equity ratio below industry norms.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 7:01 pm

MELI

Recent analyst ratings for MercadoLibre (NASDAQ:MELI) show a predominantly bullish outlook, with an average 12-month price target of $1998.75, marking an 8.14% increase from the previous target. The company's financial performance indicates strong growth and profitability, with a notable revenue growth rate of 41.94% and a net margin of 3.87%. MercadoLibre operates Latin America's largest e-commerce marketplace, benefiting from diverse revenue streams and a solid market position.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 7:00 pm

DRI

Analyst ratings for Darden Restaurants (NYSE:DRI) show varied opinions over the last quarter, with a summary of 19 analysts' ratings indicating a shift towards bullish sentiment. The average 12-month price target is $186.05, reflecting a 1.53% increase from the previous target. Analyst actions include both upgrades and downgrades, with price targets ranging from $165.00 to $200.00. Darden Restaurants, a leading U.S. full-service restaurant operator, reported a revenue of $10.5 billion in fiscal 2023, achieving a 9.68% revenue growth rate and a net margin of 7.78%, but faces challenges with a high debt-to-equity ratio of 2.71.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 7:00 pm